Renaissance Technologies LLC Invests $654,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)

Renaissance Technologies LLC bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 14,300 shares of the company’s stock, valued at approximately $654,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. American Century Companies Inc. raised its position in Keros Therapeutics by 24.9% during the second quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock valued at $13,626,000 after purchasing an additional 59,364 shares during the period. Quest Partners LLC boosted its stake in Keros Therapeutics by 23,945.0% during the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock worth $220,000 after buying an additional 4,789 shares during the period. Arizona State Retirement System boosted its stake in Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after buying an additional 1,130 shares during the period. Rhumbline Advisers increased its position in Keros Therapeutics by 20.6% during the second quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock valued at $1,903,000 after acquiring an additional 7,111 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Keros Therapeutics by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after acquiring an additional 18,755 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.90% of the stock is currently owned by company insiders.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock opened at $59.67 on Wednesday. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -11.59 and a beta of 1.23. The business has a 50-day moving average of $51.27 and a 200 day moving average of $52.28. Keros Therapeutics, Inc. has a 12 month low of $27.02 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The company had revenue of $0.04 million during the quarter. During the same quarter in the prior year, the company earned ($1.27) earnings per share. Equities research analysts anticipate that Keros Therapeutics, Inc. will post -4.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of recent analyst reports. Bank of America dropped their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Truist Financial reissued a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, June 18th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Finally, Oppenheimer started coverage on shares of Keros Therapeutics in a research note on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $90.63.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.